ADVANCES IN PHARMACOLOGY VOL 23.

Bibliographic Details
Main Author:	August, J. Thomas
Corporate Author:	ScienceDirect (Online service)
Other Authors:	Murad, Ferid, Anders, M. W.
Format:	eBook
Language:	English
Published:	Burlington : Elsevier Science, 2014.
Series:	Advances in Pharmacology.
Subjects:	Chemotherapy. Pharmacology. Drug Therapy Pharmacology Chimiothérapie. Pharmacologie. pharmacology. Chemotherapy Electronic books.
Online Access:	Connect to the full text of this electronic book

Table of Contents:

Front Cover; Advance in Pharmacology, Volume 23; Copyright Page; Contents; Contributors; Chapter 1. Advanced Glycosylation: Chemistry, Biology, and Implications for Diabetes and Aging; I. Introduction; II. Nonenzymatic Glycosylation; III. Advanced Glycosylation; IV. Biological Consequences of Advanced Glycosylation; V. Pharmacological Inhibition; VI. Conclusion; References; Chapter 2. Complex Carbohydrates in Drug Development ; I. Introduction; II. Glycoconjugate Structure and Biosynthesis; III. Bioactivity and Pharmaceutical Potential of Complex Carbohydrates.
IV. Conclusions and PerspectivesReferences; Chapter 3. New Developments in Enteric Bacterial Toxins ; I. Overview; II. Cholera-like Enterotoxins (CT, LT-I, LT-II); III. Heat-Stable Enterotoxins (STa and STb); lV. Other Potential Escherichia coli and Vibrio cholerae Enterotoxins; V. Clostridium difficile Toxins A and B; VI. Shiga and Shiga-like Toxins; VII. Staphylococcal Enterotoxins; VIII. Clostridium Perfringens Enterotoxin A; IX. Conclusion; References; Chapter 4. Superoxide Dismutase: Pharmacological Developments and Applications; I. Introduction.
II. The Protein Chemistry and Enzymology of the Superoxide DismutasesIII. The Superoxide Radical: Toxicity versus Reactivity; IV. The Pathological Production of Superoxide Radical; V. The Pharmacodynamics and Pharmacokinetics of the Superoxide Dismutases; VI. Chemical Modification of Superoxide Dismutases; VII. Genetic Modification of Superoxide Dismutases; VIII. Down Syndrome and the Concept of "Oxidant-Antioxidant Balance"; IX. Concluding Remarks; References; Chapter 5. Pharmacological Implications of Interleukin-5 in the Control of Eosinophilia; I. Introduction.
II. Biochemistry of Interleukin-5III. Biological Properties of Interleukin-5; IV. Control of Eosinophilia; V. Eosinophils and Tumors; VI. Eosinophils and Asthma; VII. Summary and Overview; References; Chapter 6. Advances in Antiarrhythmic Drug Therapy; I. Introduction; II. Classification of Antiarrhythmic Drugs; III. Applications of Classification Systems; IV. Class I Antiarrhythmic Drugs; V. Class II Antiarrhythmic Drugs; VI. Class III Antiarrhythmic Drugs; References; Chapter 7. New Developments in Thrombolytic Therapy ; I. Introduction; II. Currently Available Plasminogen Activators.
III. Antibody-Directed ThrombolysislV. Plasminogen Plus Plasminogen Activator Combinations; V. Thrombolysis and Anticoagulation; VI. Thrombolysis and Platelets; VII. Combinations of Plasminogen Activators; VIII. Summary; References; Chapter 8. Therapy of Hematopoietic Disorders with Recombinant Colony-Stimulating Factors; I. Overview of Normal Hematopoiesis; II. Pharmacologic Principles of Colony-Stimulating Factor Therapy; III. Clinical Uses of Colony-Stimulating Factors; Refcrences; Chapter 9. Mechanisms of Xenobiotic-Induced Renal Carcinogenicity; I. Introduction.